



# AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Corp Office: H.No 1769, Phase 3B2, Mohali-160059

Phone: 0172-5020758-69 Website: [www.ajoonibiotech.com](http://www.ajoonibiotech.com)

E-mail: [ajooni.biotech@gmail.com](mailto:ajooni.biotech@gmail.com) / [info@ajoonibiotech.com](mailto:info@ajoonibiotech.com)

CIN: L85190PB2010PLC040162

Date: May 26, 2025

To,  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400051

Dear Sir / Madam,

**Subject: Revised Submission of Financial Results for the year ended on 31st March, 2025**  
**SYMBOL: AJOONI**

Dear Sir/Madam,

With reference to mail received from your good office on 25/06/2025, we are again submitting Financial results in machine readable format along with the balancing figure note inserted.

You are requested to kindly take the same on your record and acknowledge receipt.


Thanking You,  
Yours Truly,  
For Ajooni Biotech Limited

Swati Vijan  
Company Secretary  
ACS39179

**AJOONI BIOTECH LIMITED**  
CIN : L85190PB2010PLCO40162

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2025(In Lakhs)**

| PARTICULARS |                                                                                  | Quarter Ended   |                 |                 | Year Ended<br>(Audited) | Year Ended<br>(Audited) |
|-------------|----------------------------------------------------------------------------------|-----------------|-----------------|-----------------|-------------------------|-------------------------|
|             |                                                                                  | 31.03.2025      | 31.12.2024      | 31.03.2024      | 31.03.2025              | 31.03.2024              |
| <b>I</b>    | <b>Income</b>                                                                    |                 |                 |                 |                         |                         |
|             | Revenue from operations                                                          | 2,927.44        | 3,403.46        | 1,958.16        | 11469.19                | 8,011.46                |
|             | Other income                                                                     | 133.64          | 38.63           | 25.68           | 206.90                  | 219.33                  |
|             | <b>Total income from operations</b>                                              | <b>3,061.08</b> | <b>3,442.09</b> | <b>1,983.84</b> | <b>11,676.09</b>        | <b>8,230.79</b>         |
| <b>II</b>   | <b>Expenses</b>                                                                  |                 |                 |                 |                         |                         |
|             | Cost of Material Consumed                                                        | 2,259.09        | 2,924.11        | 1,526.39        | 9715.421754             | 6986.34                 |
|             | Change In Inventories                                                            | 10.87           | (24.21)         | 22.01           | -12.652136              | 48.65                   |
|             | Employee benefit expenses                                                        | 59.01           | 89.13           | 13.94           | 275.73                  | 180.05                  |
|             | Finance costs                                                                    | 5.68            | 6.83            | 11.04           | 33.43                   | 55.69                   |
|             | Depreciation and amortization expenses                                           | 38.10           | 23.75           | 23.83           | 109.353414              | 87.42                   |
|             | Other expenses                                                                   | 497.14          | 321.50          | 236.80          | 1121.88                 | 573.03                  |
|             | <b>Total expenses</b>                                                            | <b>2,869.89</b> | <b>3,341.11</b> | <b>1,834.01</b> | <b>11,243.16</b>        | <b>7,931.18</b>         |
| <b>III</b>  | <b>Profit/(Loss) before exceptional items and tax</b>                            | <b>191.18</b>   | <b>100.98</b>   | <b>149.83</b>   | <b>432.92</b>           | <b>299.61</b>           |
| <b>IV</b>   | <b>Exceptional items</b>                                                         |                 |                 |                 |                         |                         |
| <b>V</b>    | <b>Profit/(Loss) before tax</b>                                                  | <b>191.18</b>   | <b>100.98</b>   | <b>149.83</b>   | <b>432.92</b>           | <b>299.61</b>           |
| <b>VI</b>   | <b>Tax expenses</b>                                                              |                 |                 |                 |                         |                         |
|             | a) Current tax                                                                   | 49.24           | 22.22           | 59.86           | 102.42                  | 87.50                   |
|             | b) Deferred tax                                                                  | 12.44           | 5.74            | 1.51            | 6.70                    | 4.01                    |
|             | b) Mat Credit                                                                    |                 |                 |                 |                         |                         |
| <b>VII</b>  | <b>Net Profit/(Loss) for the period/year</b>                                     | <b>154.38</b>   | <b>73.02</b>    | <b>91.48</b>    | <b>337.20</b>           | <b>216.12</b>           |
| <b>VIII</b> | <b>Other comprehensive income (net of tax) loss:</b>                             | <b>(82.38)</b>  | <b>2.14</b>     | <b>59.55</b>    | <b>(26.10)</b>          | <b>(103.22)</b>         |
|             | <b>Total other comprehensive income</b>                                          | <b>(82.38)</b>  | <b>2.14</b>     | <b>59.55</b>    | <b>(26.10)</b>          | <b>-103.22</b>          |
| <b>IX</b>   | <b>Total comprehensive income for the period/year (VII+VIII)</b>                 | <b>72.00</b>    | <b>75.16</b>    | <b>151.03</b>   | <b>311.10</b>           | <b>112.90</b>           |
| <b>X</b>    | <b>Paid-up equity share capital (face value of the share shall be indicated)</b> | <b>3,444.87</b> | <b>3,444.87</b> | <b>1,752.27</b> | <b>3,444.87</b>         | <b>1,752.27</b>         |




|     |                                              |          |          |          |          |          |
|-----|----------------------------------------------|----------|----------|----------|----------|----------|
| XI  | Other equity (excluding revaluation reserve) | 5,363.02 | 5,288.88 | 2,518.51 | 5,363.02 | 2,518.51 |
| XII | EPS in Rs. (Face Value of Rs.2/- each)*      |          |          |          |          |          |
|     | -Basic                                       | 0.09     | 0.04     | 0.10     | 0.20     | 0.25     |
|     | -Diluted                                     | 0.09     | 0.04     | 0.10     | 0.20     | 0.25     |

**Notes:**

1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 23/05/2025 after being reviewed by the Audit Committee.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
3. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.
4. Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.
- 5 \*THE EPS of previous period is recalculated taking into effect of rights and split shares issue.
- 6 The figures for Quarter ended 31st March 2025 are the balancing figures between audited figures in respect of the financial year and the published year to date figures upto nine months ended 31st December 2024.

Place : Mohali  
Date : 26/05/2025

For Afooni Biotech Limited  
  
 Jasjit Singh  
 Managing Director  
 DIN: 01937631

## Statement of Assets and Liabilities For the Year ended on 31st March 2025

| PARTICULARS | 31 <sup>ST</sup><br>MARCH<br>2025 | 31 <sup>ST</sup> MARCH 2024 |
|-------------|-----------------------------------|-----------------------------|
|-------------|-----------------------------------|-----------------------------|


### I. ASSETS

#### (1) Non - Current Assets

|                                               |         |         |
|-----------------------------------------------|---------|---------|
| a) Property, Plant and Equipment              | 1093.31 | 1031.89 |
| b) Capital Work In Progress                   | 29.29   | 92.45   |
| c) Investment Property                        | -       | -       |
| d) Goodwill                                   | -       | -       |
| e) Other Intangible Assets                    | 47.93   | -       |
| f) Intangible Assets Under Development        | -       | -       |
| g) Biological Assets other than Bearer Plants | -       | -       |
| h) Financial Assets                           |         |         |
| (1) Investments                               | 349.36  | 213.63  |
| (2) Trade Receivables                         |         |         |
| (3) Loans                                     |         |         |
| (4) Other Financial Assets                    | 1506.79 |         |
| i) Deffered Tax Asset (net)                   | 37.92   | 31.22   |
| j) Other Non Current Asset                    | 240.11  | 150.00  |

#### (2) Current Assets

|                                          |         |         |
|------------------------------------------|---------|---------|
| a) Inventories                           | 2398.69 | 1536.73 |
| b) Financial Assets                      |         |         |
| (1) Investments                          |         |         |
| (2) Trade Receivables                    | 1621.64 | 1295.94 |
| (3) Cash & Cash Equivalent               | 683.02  | 42.82   |
| (4) Bank Balances other than (iii) above |         |         |
| (5) Loans                                | 1330.65 | 351.42  |
| (6) Other Financial Asset                | 27.37   |         |
| c) Current Tax Assets (net)              |         |         |
| d) Other Current Asset                   | 139.03  | 5.93    |



|                                         |                                       |         |         |         |
|-----------------------------------------|---------------------------------------|---------|---------|---------|
|                                         |                                       | TOTAL   |         |         |
|                                         |                                       | Rs.     | 9505.11 | 4752.04 |
| <b><u>II EQUITY AND LIABILITIES</u></b> |                                       |         |         |         |
| <b><u>(1)</u></b>                       | <b><u>Equity</u></b>                  |         |         |         |
|                                         | a) Equity Share Capital               | 3444.87 | 1752.27 |         |
|                                         | b) Other Equity                       | 5363.02 | 2518.51 |         |
| <b><u>(2)</u></b>                       | <b><u>Non-Current Liabilities</u></b> |         |         |         |
|                                         | a) Financial Liabilities              |         |         |         |
|                                         | (1) Borrowings                        | 193.97  | 168.20  |         |
|                                         | (2) Trade Payables                    |         |         |         |
|                                         | (3) Other Financial Liabilities       |         |         |         |
|                                         | b) Employee Benefit Obligations       | 21.13   | 11.99   |         |
|                                         | c) Deferred Tax Liability (net)       | -       | -       |         |
|                                         | d) Other Non Current Liability        | -       | -       |         |
| <b><u>(3)</u></b>                       | <b><u>Current Liabilities</u></b>     |         |         |         |
|                                         | a) Financial Liabilities              |         |         |         |
|                                         | (1) Borrowings                        | 0.00    | 48.57   |         |
|                                         | (2) Trade Payables                    | 349.52  | 158.45  |         |
|                                         | (3) Other Financial Liabilities       |         |         |         |
|                                         | b) Employee Benefit Obligations       | 0.93    | 1.05    |         |
|                                         | c) Other Current Liabilities          | 29.25   | 5.48    |         |
|                                         | d) Current tax liabilities (Net)      | 102.42  | 87.50   |         |
|                                         |                                       | TOTAL   |         |         |
|                                         |                                       | Rs.     | 9505.11 | 4752.04 |

Date: 26.05.2025

Place: Mohali

For Ajooni Biotech Limited

7705

Jasjot Singh  
Managing Director  
DIN: 01937631





**NARINDER KUMAR AND COMPANY**  
**CHARTERED ACCOUNTANTS**

SCO 65-B (1st Floor) City Heart,  
Kharar Chandigarh Road,  
Kharar, SAS Nagar Mohali-140301  
Mobile : 98154 50065  
Email : nkgargca@yahoo.co.in

Ref. No. ....

Dated .....

**Independent Auditor's Report**

To

**The Members of M/s Ajooni Biotech Limited**

**Opinion**

We have audited the accompanying standalone financial statements of **M/s Ajooni Biotech Limited** which comprise the Balance Sheet as at March 31, 2025, the Statement of Profit and Loss (statement of changes in equity), Cash Flow Statement for the year then ended, notes to the financial statements and a summary of significant accounting policies and other explanatory information. These financial statements are the responsibility of the company's management. Our responsibility is to express an opinion on these financial statements based on our audit.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid (Standalone) financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2025, and its Profit, (changes in equity) for the year ended on that date.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Key Audit Matters**

Key Audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.



## **Management's Responsibility for the Standalone Financial Statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, (changes in equity) and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

## **Auditor's Responsibility for the audit of the Standalone Financial Statements**

Our responsibility is to express an opinion on these (Standalone) financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

## **Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the **Annexure-A**, a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by section 143 (3) of the Act, we report that:
  - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;



- b) In our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- c) The Balance Sheet, the Statement of Profit and Loss dealt with by this Report are in agreement with the books of account
- d) In our opinion, the aforesaid (Standalone) financial statements comply with the Accounting Standards specified under section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of written representations received from the directors as on March 31, 2025 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2025 from being appointed as a director in terms of Section 164 (2) of the Act.
- f) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
  - i. The Company does not have any pending litigations which would impact its financial position.
  - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
  - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.



For NARINDER KUMAR AND COMPANY.

Chartered Accountants

FRN: 0030737N

CA NARINDER KUMAR GARG  
(PARTNER)

M.No 080287

Date: 26/05/2025

Place: MOHALI

UDIN: 25080287BMLITD5360

## **Annexure A” to the Independent Auditors’ Report**

Referred to in paragraph 1 under the heading ‘Report on Other Legal & Regulatory Requirement’ of our report of even date to the financial statements of the Company for the year ended March 31, 2025:

- 1) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets;
  - (b) The Fixed Assets have been physically verified by the management in a phased manner, designed to cover all the items over a period of three years, which in our opinion, is reasonable having regard to the size of the company and nature of its business. Pursuant to the program, a portion of the fixed asset has been physically verified by the management during the year and no material discrepancies between the books records and the physical fixed assets have been noticed.
  - (c) The title deeds of immovable properties are held in the name of the company.
  - (d) The company has not revalued its Property, Plant and Equipment during the year.
  - (e) No proceedings have been initiated against the company for holding any Benami Property under the Benami Transactions (Prohibition) Act 1988 and rules made there under.
- 
- 2) (a) The Management has conducted Physical verification of inventory at reasonable intervals and according to our opinion is reasonable having regard to the size of the company and nature of its business. There were No Discrepancies noticed on physical verification of the inventory.
  - (b) The quarterly returns or statements filed by company with banks or financial institutions are in agreement with the books of accounts.
- 
- 3) a) The Company has not granted any loans or provided any advances in nature of Loans , secured or unsecured to Companies , firms , Limited Liability Partnerships or any other party.  
The company had only provided advance for purchase of land which is not considered as nature of Loan as per nature of agreement and management representation
  - 4) In our opinion and according to the information and explanations given to us, the company has complied with the provisions of section 185 and 186 of the Companies Act, 2013 In respect of loans, investments, guarantees, and security.
- 
- 5) The Company has not accepted deposits from the public and hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the public are not applicable.
- 
- 6) As informed to us, the maintenance of Cost Records has not been specified by the Central Government under sub-section (1) of Section 148 of the Act, in respect of the activities carried on by the company.



7) (a) According to information and explanations given to us and on the basis of our examination of the books of account, and records, the Company has been generally regular in depositing undisputed statutory dues including Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs, Duty of Excise, Goods and Service Tax, Cess and any other statutory dues with the appropriate authorities due to deposited. According to the information and explanations given to us, no undisputed amounts payable in respect of the above were in arrears as at March 31, 2025 for a period of more than six months from the date on when they become payable.

The provisions of gratuity are applicable to the company , provision of Rs 22,06,720 in books of accounts but is unpaid till the date as there has been no termination / resignation/retirement of any employee covered under gratuity provisions.

b) According to the information and explanation given to us, there are no dues of income tax, GST, duty of customs, duty of excise, value added tax outstanding on account of any dispute.

8)According to the information and explanation given to us, there are no transactions which have been surrendered or disclosed as income during the year in tax assessment under Income tax Act ,1961.

9) a) In our opinion and according to the information and explanations given to us, the Company has not defaulted in the repayment of dues to banks.

b) In our opinion and according to the information and explanations given to us, the company is not declared as wilful defaulter by any bank or financial institution or other lender.

c) In our opinion and according to the information and explanations given to us Long term Loans were applied for the purpose they were obtained.

d) In our opinion and according to the information and explanations given to us funds raised on Short term basis were applied for the purpose they were obtained.

e) In our opinion and according to the information and explanations given to us, the company has not taken any funds from entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures.

f) The company had raised the following Loan on pledge of security from M/s Khanna Solvex , partnership firm in which Mr Jasjot Singh Managing Director/CFO of the company , being a Partner and security of Land & Building at D-118, Industrial Area Phase-7 Mohali, Market Value 500 Lacs owned by M/s Healthy Biosciences Limited in which Mr Gursimran Singh is common director .LOAN OBTAINED: HDFC Bank CC OF 10.00 Cr ,EMT of Land & Building at D-118, Industrial Area Phase-7



Mohali, Market Value 500 Lacs owned by M/s Healthy Biosciences Limited. Additional EMT OF industrial Property in Khanna, MV 500 LACS held in name of M/s Khanna Solvex. However Security given by Healthy Biosciences Limited has been got released subsequent to the date of Balance sheet.

10) Based upon the audit procedures performed and the information and explanations given by the management, the company has raised an amount of Rs. 4231.49 lakhs @ Rs. 5 each including premium of Rs. 3 each by way of rights issue during the year. b) Based upon the audit procedures performed and the information and explanations given by the management, the requirements of Section 62 of the Companies Act 2013 are not applicable on the company

11) Based upon the audit procedures performed and the information and explanations given by the management, we report that no fraud by the Company or on the company by its officers or employees has been noticed or reported during the year.

12) In our opinion, the Company is not a Nidhi Company. Therefore, the provisions of clause (xii) of the Order are not applicable to the Company.

13) In our opinion, all transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 and the details have been disclosed in the Financial Statements as required by the applicable accounting standards.

14) In our opinion, the company has an internal audit system to commensurate with the size and nature of its business,

b) The reports of Internal Auditor dated 24.04.2025 were considered while forming an opinion on financial statements.

15) Based upon the audit procedures performed and the information and explanations given by the management, the company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, the provisions of clause (xiv) of the Order are not applicable to the Company and hence not commented upon.

16) In our opinion, the company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions of clause (xvi) of the Order are not applicable to the Company and hence not commented upon.



17) In our opinion, the company has not incurred any cash losses in the financial year and in any preceding financial year.

18) There is no resignation of the statutory auditor during the year, accordingly, the provisions of clause (Xviii) of the Order are not applicable to the Company and hence not commented upon.

19) In our opinion, on the basis of financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of Board of directors and management's plans no material uncertainty exists as on date of audit report that company is not capable of meeting its liabilities at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.

20) In our opinion, the Provisions of Section 135(5) Of the Companies Act 2013 are not applicable to the company, the provisions of clause (xx) of the Order are not applicable to the Company and hence not commented upon.

21) In our opinion the financial statements are stand alone statement and consolidation is not required, the provisions of clause (xxi) of the Order are not applicable to the Company and hence not commented upon.

For NARINDER KUMAR AND COMPANY.

Chartered Accountants

FRN: 0030737N



*Narinder*

CA NARINDER KUMAR GARG  
(PARTNER)  
M.No 080287

Date: 26/05/2025

UDIN:- 25080287BMLITD5360

**Annexure B” to the Independent Auditor’s Report of even date on the Financial Statements of M/s Ajooni Biotech Limited**

**Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)**

We have audited the internal financial controls over financial reporting of M/s Ajooni Biotech Limited (“the Company”) as of March 31, 2025 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

**Management’s Responsibility for Internal Financial Controls**

The Company’s management is responsible for establishing and maintaining internal financial controls. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

**Auditors’ Responsibility**

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal



financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

### **Meaning of Internal Financial Controls Over Financial Reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

### **Inherent Limitations of Internal Financial Controls Over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.



## Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2025.

For NARINDER KUMAR AND COMPANY.

Chartered Accountants

FRN: 0030737N



*Narinder Kumar Garg*

CA NARINDER KUMAR GARG

(PARTNER)

M.No 080287

Date: 26/05/2025

UDIN:- 25080287BMLITD5360



# AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Corp Office: H.No 1769, Phase 3B2, Mohali-160059

Phone: 0172-5020758-69 Website: [www.ajoonibiotech.com](http://www.ajoonibiotech.com)

E-mail: [ajooni.biotech@gmail.com](mailto:ajooni.biotech@gmail.com) / [info@ajoonibiotech.com](mailto:info@ajoonibiotech.com)

CIN: L85190PB2010PLC040162

## **DECLARATION ON UNMODIFIED OPINION**

[Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015]

Pursuant to the requirement as specified by regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended by SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016 it is hereby declared that the Auditors Report for the Financial Year ended on March 31, 2025 contains unmodified opinion as provided under the Independent Auditor's Report which is attached herewith for your reference.

You are kindly requested to take the above declaration in your records.

**For Ajooni Biotech Limited**

**Jasjot Singh**  
**Managing Director**  
**DIN: 01937631**